Loading clinical trials...
Loading clinical trials...
A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20124 in Patients with Advanced Solid Tumors
Conditions
Interventions
HS-20124 (Phase Ia：Dose escalation )
HS-20124 (Phase Ib: Dose expansion)
Locations
1
China
Affiliated Cancer Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Start Date
October 30, 2024
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2027
Last Updated
January 8, 2025
NCT07186842
NCT03514368
NCT07371663
NCT07161310
NCT07114627
NCT06666270
Lead Sponsor
Hansoh BioMedical R&D Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions